Lumira Capital IV wins commitment from BC Tech Fund
BC Tech Fund has made an undisclosed commitment to Lumira Capital IV, the fourth healthcare and life sciences fund of Canadian venture capital firm Lumira Capital. Dr. Richard Glickman, chairman and CEO of Victoria, British Columbia-based Aurinia Pharmaceuticals Inc (Nasdaq: AUPH, TSX: AUP), a Lumira portfolio company, was concurrently named a partner at the firm. Earlier this week, Vancouver's Zymeworks Inc, another Lumira portfolio company, filed to go public. Capitalized at $100 million, BC Tech Fund was launched last year under the management of Kensington Capital Partners.
4 April 2017•4 mins read
